Compare CAAS & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAS | ENTA |
|---|---|---|
| Founded | N/A | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.7M | 407.5M |
| IPO Year | N/A | 2013 |
| Metric | CAAS | ENTA |
|---|---|---|
| Price | $4.28 | $14.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 30.8K | ★ 298.8K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.68 | N/A |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $725,260,000.00 | $65,324,000.00 |
| Revenue This Year | N/A | $0.99 |
| Revenue Next Year | N/A | $0.19 |
| P/E Ratio | $3.86 | ★ N/A |
| Revenue Growth | ★ 16.72 | N/A |
| 52 Week Low | $3.50 | $4.09 |
| 52 Week High | $5.37 | $15.34 |
| Indicator | CAAS | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 67.09 |
| Support Level | $4.06 | $13.75 |
| Resistance Level | $4.30 | $14.79 |
| Average True Range (ATR) | 0.13 | 0.74 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 62.22 | 90.89 |
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.